Compass Therapeutics (CMPX) announced a corporate and financial update. Top-line Phase 2/3 data readout for CTX-009, now named tovecimig, in patients with biliary tract cancer is on track for end of Q1 2025. CTX-10726 is advancing as a new drug candidate after a year of preclinical development, with YE 2025 IND expected. Two Phase 2 biomarker trials are expected to initiate in mid-2025: tovecimig and CTX-471. Fully enrolled the third dosing cohort of the Phase 1 dose-escalation study of CTX-8371 with preliminary data expected in the second half of 2025. Estimated $127 million in cash and marketable securities at YE 2024, which is expected to provide cash runway into Q1 2027.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics initiated with a Buy at D. Boral Capital
- Compass Therapeutics Appoints New CFO Amid Strategic Moves
- Compass Therapeutics appoints Shin as Chief Financial Officer
- Compass downgrade ‘curious,’ presents upside, says H.C. Wainwright
- Compass Therapeutics downgraded to Market Perform from Outperform at Leerink